Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00472_DB08920_nanopub.RA5PV1V_tA4XW_90V2JyyX6uC6ELOAWBm6PWqDjCsJLqE#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00472_DB08920 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00472_DB08920 label "DDI between Fluoxetine and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Fluoxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00472_DB08920]" assertion.
- drugbank_resource:DB00472_DB08920 identifier "drugbank_resource:DB00472_DB08920" assertion.
- drugbank_resource:DB00472_DB08920 title "DDI between Fluoxetine and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Fluoxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if fluoxetine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00472 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00472_DB08920 assertion.
- drugbank:DB08920 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00472_DB08920 assertion.